BioPharma Dive March 22, 2024
Patients with Part D plans and who have a history of heart disease are now able to receive Wegovy, a shift that could further spur use of the fast-selling medicine.
Medicare will cover the costs of Novo Nordisk’s obesity drug Wegovy for some patients with a history of heart disease, a policy shift that could significantly open up access to the in-demand weight loss medicine.
A spokesperson for the Centers for Medicare & Medicaid Services confirmed on Thursday that obesity drugs receiving Food and Drug Administration approval for an “additional medically accepted indication” may now be covered under so-called Part D plans. Those accepted uses include an approval to reduce the risk of heart problems or treat diabetes, the...
Today's Sponsors
Today's Sponsor